The analysis included 14,019 cases of the Delta variant – 166 of whom were hospitalised – between April 12 and June 4.

Are we still going to use it? Can we just scrap it? Do we have enough Pfizer? With more changing health advice and discussion ...

Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...

LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...

Good news for Pfizer could be good news for AstraZeneca, for two reasons. First, President Trump hinted in the press conference earlier this week that other deals similar to Pfizer's could be on the ...

Pfizer ($PFE) appears to be speeding toward a crucial early FDA approval for palbociclib, a breast cancer treatment with blockbuster potential, pivoting from its ...